Format

Send to

Choose Destination
Immunol Allergy Clin North Am. 2015 Aug;35(3):577-98. doi: 10.1016/j.iac.2015.05.007.

Novel Therapies for Eosinophilic Disorders.

Author information

1
Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, 240 East Huron Street, Room M-306, Chicago, IL 60611, USA. Electronic address: bruce.bochner@northwestern.edu.

Abstract

Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.

KEYWORDS:

Antibodies; Biomarkers; Eosinophil; Pharmacology; Targets; Therapies

PMID:
26209901
PMCID:
PMC4515571
DOI:
10.1016/j.iac.2015.05.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center